{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:01:09Z","timestamp":1793138469816,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["R01DK135645"],"award-info":[{"award-number":["R01DK135645"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["P30DK45735"],"award-info":[{"award-number":["P30DK45735"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["UL1RR024139"],"award-info":[{"award-number":["UL1RR024139"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK135645"],"award-info":[{"award-number":["R01DK135645"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK45735"],"award-info":[{"award-number":["P30DK45735"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022752","name":"Merck Sharp & Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Metabolism"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cmet.2024.07.023","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T10:34:46Z","timestamp":1724754886000},"page":"2359-2366.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Glucagon promotes increased hepatic mitochondrial oxidation and pyruvate carboxylase flux in humans with fatty liver disease"],"prefix":"10.1016","volume":"36","author":[{"given":"Kitt Falk","family":"Petersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajahat Z.","family":"Mehal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1529-5668","authenticated-orcid":false,"given":"Gerald I.","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmet.2024.07.023_bib1","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1053\/gast.2002.36572","article-title":"AGA technical review on nonalcoholic fatty liver disease","volume":"123","author":"Sanyal","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2024.07.023_bib2","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2024.07.023_bib3","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s10620-013-2743-5","article-title":"Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"58","author":"Stepanova","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.cmet.2024.07.023_bib4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cmet.2011.11.004","article-title":"Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease","volume":"14","author":"Sunny","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2024.07.023_bib5","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2024.07.023_bib6","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2003.50095","article-title":"Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis","volume":"37","author":"Chalasani","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2024.07.023_bib7","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1053\/j.gastro.2010.05.039","article-title":"Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals","volume":"139","author":"Iozzo","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2024.07.023_bib8","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2024.07.023_bib9","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/hep.32324","article-title":"Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD","volume":"76","author":"Moore","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2024.07.023_bib10","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.282.17.1659","article-title":"Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study","volume":"282","author":"Cortez-Pinto","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.cmet.2024.07.023_bib11","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1136\/gutjnl-2012-302789","article-title":"Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease","volume":"62","author":"Croci","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.cmet.2024.07.023_bib12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2337\/dc10-1076","article-title":"Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes","volume":"34","author":"Schmid","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmet.2024.07.023_bib13","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.26226","article-title":"Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease","volume":"58","author":"Begriche","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cmet.2024.07.023_bib14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2009.11.030","article-title":"Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model","volume":"52","author":"Rector","year":"2010","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.cmet.2024.07.023_bib15","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1478-3231.2009.02076.x","article-title":"Liver fat and lipid oxidation in humans","volume":"29","author":"Kotronen","year":"2009","journal-title":"Liver Int."},{"key":"10.1016\/j.cmet.2024.07.023_bib16","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1113\/JP272105","article-title":"Hepatic mitochondrial oxidative phosphorylation is normal in obese patients with and without type 2 diabetes","volume":"594","author":"Lund","year":"2016","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.cmet.2024.07.023_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2016.06.005","article-title":"Assessment of hepatic mitochondrial oxidation and pyruvate cycling in NAFLD by (13)C magnetic resonance spectroscopy","volume":"24","author":"Petersen","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2024.07.023_bib18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"Bl\u00fcher","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmet.2024.07.023_bib19","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(18)30726-8","article-title":"MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study","volume":"391","author":"Ambery","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2024.07.023_bib20","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1038\/s41598-022-10577-2","article-title":"Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis","volume":"12","author":"Nestor","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cmet.2024.07.023_bib21","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","article-title":"LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial","volume":"400","author":"Urva","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2024.07.023_bib22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u00a0\u2013 a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2024.07.023_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cmet.2024.07.023_bib24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2024.07.023_bib25","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2024.07.023_bib26","first-page":"218","article-title":"Resmetirom proves positive for NASH with liver fibrosis","volume":"21","author":"Ray","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2024.07.023_bib27","doi-asserted-by":"crossref","first-page":"154707","DOI":"10.1016\/j.metabol.2021.154707","article-title":"Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters","volume":"117","author":"Briand","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.cmet.2024.07.023_bib28","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s12328-021-01491-7","article-title":"Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"14","author":"Malik","year":"2021","journal-title":"Clin. J. Gastroenterol."},{"key":"10.1016\/j.cmet.2024.07.023_bib29","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmet.2024.07.023_bib30","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S2468-1253(23)00198-X","article-title":"Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"8","author":"Noureddin","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.cmet.2024.07.023_bib31","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2013.10.004","article-title":"Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler","volume":"18","author":"Perry","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2024.07.023_bib32","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1126\/science.aaa0672","article-title":"Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats","volume":"347","author":"Perry","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cmet.2024.07.023_bib33","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41586-020-2074-6","article-title":"Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis","volume":"579","author":"Perry","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cmet.2024.07.023_bib34","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1096\/fj.201700001R","article-title":"A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice","volume":"31","author":"Abulizi","year":"2017","journal-title":"FASEB J."},{"key":"10.1016\/j.cmet.2024.07.023_bib35","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1194\/jlr.RA119000586","article-title":"Membrane-bound sn-1,2-diacylglycerols explain the dissociation of hepatic insulin resistance from hepatic steatosis in MTTP knockout mice","volume":"61","author":"Abulizi","year":"2020","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.cmet.2024.07.023_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13539","article-title":"Sex- and strain-specific effects of mitochondrial uncoupling on age-related metabolic diseases in high-fat diet-fed mice","volume":"21","author":"Goedeke","year":"2022","journal-title":"Aging Cell"},{"key":"10.1016\/j.cmet.2024.07.023_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay0284","article-title":"Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates","volume":"11","author":"Goedeke","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cmet.2024.07.023_bib38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-pharmtox-010716-104727","article-title":"Emerging pharmacological targets for the treatment of nonalcoholic fatty liver disease, insulin resistance, and type 2 diabetes","volume":"59","author":"Goedeke","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.cmet.2024.07.023_bib39","doi-asserted-by":"crossref","first-page":"101178","DOI":"10.1016\/j.molmet.2021.101178","article-title":"Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH","volume":"46","author":"Goedeke","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.cmet.2024.07.023_bib40","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.2337\/db18-0068","article-title":"Hepatic glucagon receptor signaling enhances insulin-stimulated glucose disposal in rodents","volume":"67","author":"Kim","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2024.07.023_bib41","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2337\/db23-0233","article-title":"Liver-selective imidazolopyrazine mitochondrial uncoupler SHD865 reverses adiposity and glucose intolerance in mice","volume":"73","author":"Beretta","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2024.07.023_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01143-w","article-title":"Non-invasive assessment of hepatic mitochondrial metabolism by positional isotopomer NMR tracer analysis (PINTA)","volume":"8","author":"Perry","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cmet.2024.07.023_bib43","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.cmet.2016.12.017","article-title":"A non-invasive method to assess hepatic acetyl-CoA in\u00a0vivo","volume":"25","author":"Perry","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2024.07.023_bib44","first-page":"E121","article-title":"Effect of glucagon on hepatic fatty acid oxidation and ketogenesis in conscious dogs","volume":"237","author":"Keller","year":"1979","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.cmet.2024.07.023_bib45","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00125-005-1682-x","article-title":"Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms","volume":"48","author":"Bugianesi","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmet.2024.07.023_bib46","doi-asserted-by":"crossref","first-page":"12161","DOI":"10.1074\/jbc.M116.720631","article-title":"Propionate increases hepatic pyruvate cycling, anaplerosis and alters mitochondrial metabolism","volume":"291","author":"Perry","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.cmet.2024.07.023_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav0120","article-title":"The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans","volume":"11","author":"Tirosh","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cmet.2024.07.023_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002336","article-title":"Acute effects of the food preservative propionic acid on glucose metabolism in humans","volume":"9","author":"Adler","year":"2021","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.cmet.2024.07.023_bib49","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nm.3415","article-title":"Direct assessment of hepatic mitochondrial oxidative and anaplerotic fluxes in humans using dynamic 13C magnetic resonance spectroscopy","volume":"20","author":"Befroy","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.cmet.2024.07.023_bib50","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.cell.2015.01.012","article-title":"Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes","volume":"160","author":"Perry","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.cmet.2024.07.023_bib51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cmet.2024.07.023_bib52","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2337\/diabetes.54.3.603","article-title":"Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes","volume":"54","author":"Petersen","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.cmet.2024.07.023_bib53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/dtb.2022.000055","article-title":"Very low calorie diets and total diet replacement in type 2 diabetes: where are we now?","volume":"62","author":"Taylor","year":"2024","journal-title":"Drug Ther. Bull."},{"key":"10.1016\/j.cmet.2024.07.023_bib54","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/oby.23141","article-title":"Prolonged glucagon infusion does not affect energy expenditure in individuals with overweight\/obesity: a randomized trial","volume":"29","author":"Whytock","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.cmet.2024.07.023_bib55","doi-asserted-by":"crossref","first-page":"100485","DOI":"10.1016\/j.jlr.2023.100485","article-title":"From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease","volume":"65","author":"Rinella","year":"2024","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.cmet.2024.07.023_bib56","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.cmet.2023.10.008","article-title":"The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans","volume":"35","author":"Luukkonen","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.cmet.2024.07.023_bib57","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157906","article-title":"Ethnic and sex differences in hepatic lipid content and related cardiometabolic parameters in lean individuals","volume":"7","author":"Petersen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.cmet.2024.07.023_bib58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cct.2017.07.015","article-title":"Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: the TARGET-NASH study","volume":"61","author":"Barritt","year":"2017","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.cmet.2024.07.023_bib59","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmet.2024.07.023_bib60","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/ajcn\/36.5.936","article-title":"A short questionnaire for the measurement of habitual physical activity in epidemiological studies","volume":"36","author":"Baecke","year":"1982","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.cmet.2024.07.023_bib61","doi-asserted-by":"crossref","first-page":"13705","DOI":"10.1073\/pnas.1110105108","article-title":"Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals","volume":"108","author":"Rab\u00f8l","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cell Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413124003255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1550413124003255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:22:33Z","timestamp":1762550553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1550413124003255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1550413124003255"],"URL":"https:\/\/doi.org\/10.1016\/j.cmet.2024.07.023","relation":{},"ISSN":["1550-4131"],"issn-type":[{"value":"1550-4131","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon promotes increased hepatic mitochondrial oxidation and pyruvate carboxylase flux in humans with fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Cell Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmet.2024.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}